Recent large-scale phase III clinical trials of drugs directly targeting the Aβ-related pathways involved in AD have failed to benefit patients[47,48], and therapeutic approaches targeting tau are gaining attention because reducing tau can ameliorate Aβ-induced toxicity[11,15,49,50] and rescue the toxicity in mouse mutant tau transgenic models[51-54]. This evidence concerns the gene MAPT and Alzheimer disease.